Abstract 16373: Hospitalization and Mortality in Elderly Cardio-renal Patients with Iron Deficiency Anemia Receiving Intravenous Iron Therapy: A Five Year Follow-Up from a Pilot Study
Background: In a previous pilot, double-blind, placebo-controlled study (JACC 2007; 50:1657-65), intravenous (i.v) iron without erythropoeisis stimulating agents (ESA) substantially preserved improved LVEF (%), exercise capacity, NT-pro-BNP, CRP, renal function, and quality of life in iron deficient, anemic patients with CKD and heart failure (HF). The present study evaluates hospitalization and mortality in the same group of patients after a follow-up of 1 and 5 years.
Methods: 40 patients with CKD and HF (mean age >74years) from the original pilot study were evaluated after a follow-up of 1 and 5 years. Inclusion criteria: hemoglobin (Hb g/dl) <12.5 for men and <11.5 for women; TSAT<20%; ferritin<100ng/ml; CrCl <90ml/min and left LVEF% <35%. Group -A (Control): isotonic saline solution (ISS); Group -B: Iron Sucrose Complex (ISC). Patients received a weekly infusion of ISS or 200mg ISC during 5 weeks. Patients did not receive ESA before or during the study.
Conclusions: Despite the small number of patients, the present data suggest that i.v. iron therapy without ESA may reduce hospitalization and mortality in iron deficiency, anemic CKD patients with HFand iron deficiency anemia.
- © 2012 by American Heart Association, Inc.